Berlin, 30 March 2023 - Eckert & Ziegler AG (ISIN DE0005659700, TecDAX) achieved sales of € 222.3 million in FY 2022. Compared to the previous year, sales increased by € 41.9 million or 23%. Net income reached € 29.3 million, thus increasing by nearly 20% compared to the previous year's figure adjusted for special effects.

In the Isotope Products segment, sales rose by 37% to € 131.4 million. The reason for the increase is the acquisition of the Argentinian Tecnonuclear S.A. in 2022 and a strong Asian business.

In the Medical segment, revenue grew by 8% to € 90.9 million. The largest growth driver continues to be the business with radiopharmaceuticals, which showed growth of 37% to
€ 66.4 million across all segments.

Cash and cash equivalents as of 31 December 2022 decreased to € 82.7 million; less loan liabilities, net liquidity amounted to € 60.3 million. Compared to the end of 2021, this corresponds to a decrease of € 27.6 million.

For the 2023 financial year, the Executive Board expects to achieve revenues of nearly € 230 million in the operating segments - Medical and Isotopes Products - and, as in 2022, a net profit of € 31 million. No revenues are expected in the Other segment. However, higher expenses for non-capitalizable clinical developments will occur in this segment in 2023, which will increase the loss in the Other segment by € 4 million to € 6 million. The consolidated net income (net profit) as the total of all segments will then amount to around € 25 million in 2023.

The forecast is based on a weighted average exchange rate of USD 1.05 per euro and the assumption that Eckert & Ziegler will not be affected by any major disruptions from the war in Ukraine.

The Executive Board and Supervisory Board will propose a dividend of € 0.50 per dividend-bearing share (previous year € 0.50) at the Annual General Meeting.

The full 2022 financial statements can be found here:

About Eckert & Ziegler.
Eckert & Ziegler Strahlen- und Medizintechnik AG with nearly 1.000 employees is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

For enquiries please contact:
Eckert & Ziegler AG, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138
,